Moderna, Inc. (MRNA) stock intrinsic value fair value estimate & owner earnings analysis

Moderna sells three mRNA vaccines: Spikevax and mNEXSPIKE for COVID-19, and mRESVIA for RSV. mNEXSPIKE was approved by the FDA in May 2025 and launched in the third quarter of 2025. Revenue has fallen every year since the pandemic peak: $19.3 billion in 2022, $6.8 billion in 2023, $3.2 billion in 2024 and $1.9 billion in 2025. About 62% of 2025 revenue came from the United States, about 3% from Europe and about 36% from the rest of the world. What the business earns for owners. We measure owner earnings as operating cash flow, less swings in working capital, less stock-based compensation (treated as a real cost), less the capital spending needed to keep the plants running. On that basis Moderna earned about $28.24 per share in 2021 and $19.09 in 2022, both driven by pandemic vaccine orders. It then lost $12.62 per share in 2023, $11.47 in 2024 and $7.15 in 2025. We do not treat 2021 and 2022 as a normal level, because the demand behind them has reversed. The 2023 to 2025 median is a loss of $11.47 per share, so the business as it stands has no positive earning power to capitalise. The loss narrowed by about 37% in 2025, and we assume roughly the same rate of improvement in the first year of the base case (a cash burn of about $1.9 billion, against about $3.1 billion in 2025 before interest income). Early 2026 supports that: in the first half, operating cash outflow was $1.16 billion versus $1.96 billion a year earlier, and research spending was $1.30 billion versus $1.56 billion. Because the operating business is losing money, most of the value is the cash on hand. Moderna held $8.1 billion of cash and investments at the end of 2025 (including a $600 million term loan from lenders led by Ares Capital, carrying about 9.4% interest and due November 2030) and $6.9 billion at June 30, 2026. In March 2026 Moderna settled the Arbutus/Genevant patent suit over the lipid nanoparticles used in its COVID vaccine, agreeing to pay $950 million in July 2026 and up to a further $1.3 billion if a federal appeals court rules against it on a U.S. government-contractor defense (per press reports; the filing predates the settlement). We deduct the $950 million from the cash and value the company from there, counting cash burn, loan interest and the loan repayment as cash flows. We do not separately subtract debt, and we leave out interest earned on the cash, since we already count the cash itself. Base case, about $1.20 per share. Revenue stays near $2.0 billion, with no credit for new products. Costs keep falling, but more slowly than they have: operating expenses fell 35% in 2024 and 30% in 2025, and we assume a burn of $1.9 billion, $1.5 billion, $1.1 billion, $0.7 billion and $0.3 billion in the first five years (starting July 2026), then break-even. That uses up almost all of the cash left after the settlement and the loan repayment. Nothing after that is credited, because no contract or record we can point to supports profits beyond it. The upshot: the cash roughly pays for getting the company to break-even, and the shares are worth little above zero on what is proven today. Bear case, about negative $3.20 per share. The appeals court rules against Moderna and the extra $1.3 billion falls due within about 90 days of the ruling. Revenue keeps drifting down, as it has three years in a row, and costs come down only slowly, so the burn is about $2.3 billion, $2.0 billion and $1.7 billion in the first three years. Cash would run out well before break-even, leaving a shortfall of roughly $1.3 billion after the secured loan is repaid. In that case the company would owe more than the business is worth, and new money would have to be raised on terms that heavily dilute or wipe out current shareholders. Bull case, about $15.00 per share. The company's own filed products reach the market: the seasonal flu vaccine mRNA-1010 (a late-stage efficacy study reported in October 2025 showed 26.6% relative vaccine efficacy against a standard-dose comparator in adults 50 and older) is under review in the United States, Europe, Canada and Australia, and the flu-plus-COVID combination is under review in Europe and Canada. The FDA had earlier declined to accept the flu filing, and an amended filing was made in February 2026, so timing is uncertain. In this case the UK, Canada and Australia purchase commitments hold, mNEXSPIKE takes hold in the U.S., and costs keep falling. Cash flow moves from a $1.7 billion burn in the first year to break-even in year four, then builds to earning about $0.6 billion a year for ten years, to about 2041. That endpoint is when the U.S. patents on Moderna's three current vaccines are listed to expire (Europe: 2036). Nothing is credited beyond it. What we left out. We give no value to the oncology and rare-disease programs, or to launches beyond those already filed: the filings show them in development but with no approved product or contract behind them. We also give no credit to management's stated aim to cut costs further in 2026 and 2027 beyond the pace already demonstrated. We could not size the dollar value of the UK, Canada and Australia purchase commitments from the filing, so they support the revenue level but not growth. What would prove this wrong: a much faster cost reduction, a settlement outcome that avoids the extra $1.3 billion, or a flu or combination approval with strong early sales would push value toward the bull case. Faster revenue erosion or an adverse appeals ruling would push it toward the bear case. Owner earnings for 2019 through 2025 were rebuilt from the filings; the 2019 working-capital figure relies on the main tagged cash-flow lines only and is a close approximation.